NDV-01 is a novel, sustained-release, intravesical gemcitabine/docetaxel, ready-for-use product candidate for the treatment of non-muscle invasive bladder cancer ...
Relmada Therapeutics announced a licensing agreement for NDV-01, a new treatment for non-muscle invasive bladder cancer. Phase 2 data expected in April 2025. Relmada Therapeutics, Inc. has announced ...
SurvivorNet on MSN
Muscle invasive bladder cancer: Understanding your treatment options
Radical cystectomy, or complete bladder removal, remains the standard and most effective surgery for muscle‑invasive bladder cancer because it offers the strongest chance of cure when the disease has ...
"Non Muscle Invasive Bladder Cancer – Pipeline Insight, 2026"According to DelveInsight's report, the leading Non Muscle Invasive Bladder Cancer companies include CG Oncology, Janssen Research & ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results